Steward Partners Investment Advisory’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $159K | Sell |
702
-49
| -7% | -$8.73K | ﹤0.01% | 2345 |
|
|
2026
Q1 | $130K | Hold |
751
| – | – | ﹤0.01% | 2237 |
|
|
2025
Q4 | $150K | Sell |
751
-125
| -14% | -$22.7K | ﹤0.01% | 2086 |
|
|
2025
Q3 | $137K | Buy |
876
+248
| +39% | +$39.4K | ﹤0.01% | 2058 |
|
|
2025
Q2 | $95.3K | Sell |
628
-783
| -55% | -$104K | ﹤0.01% | 2138 |
|
|
2025
Q1 | $212K | Buy |
1,411
+458
| +48% | +$76.8K | ﹤0.01% | 1619 |
|
|
2024
Q4 | $176K | Sell |
953
-119
| -11% | -$22.9K | ﹤0.01% | 1690 |
|
|
2024
Q3 | $211K | Buy |
1,072
+461
| +75% | +$95.8K | ﹤0.01% | 1503 |
|
|
2024
Q2 | $126K | Sell |
611
-109
| -15% | -$24.7K | ﹤0.01% | 1661 |
|
|
2024
Q1 | $195K | Buy |
720
+136
| +23% | +$32.5K | ﹤0.01% | 1452 |
|
|
2023
Q4 | $138K | Sell |
584
-3,304
| -85% | -$650K | ﹤0.01% | 1533 |
|
|
2023
Q3 | $762K | Sell |
3,888
-1,976
| -34% | -$406K | 0.01% | 771 |
|
|
2023
Q2 | $1.23M | Buy |
5,864
+433
| +8% | +$86.2K | 0.02% | 626 |
|
|
2023
Q1 | $1.1M | Buy |
5,431
+4,568
| +529% | +$1.04M | 0.02% | 666 |
|
|
2022
Q4 | $188K | Sell |
863
-38
| -4% | -$8.3K | ﹤0.01% | 1263 |
|
|
2022
Q3 | $177K | Sell |
901
-39
| -4% | -$8.42K | ﹤0.01% | 1250 |
|
|
2022
Q2 | $201K | Sell |
940
-5,758
| -86% | -$1.41M | ﹤0.01% | 1205 |
|
|
2022
Q1 | $1.9M | Sell |
6,698
-479
| -7% | -$148K | 0.03% | 490 |
|
|
2021
Q4 | $2.7M | Buy |
7,177
+6,595
| +1,133% | +$2.56M | 0.04% | 406 |
|
|
2021
Q3 | $240K | Sell |
582
-8
| -1% | -$3.32K | ﹤0.01% | 1200 |
|
|
2021
Q2 | $218K | Sell |
590
-65
| -10% | -$21.7K | ﹤0.01% | 1473 |
|
|
2021
Q1 | $190K | Buy |
655
+29
| +5% | +$8.06K | ﹤0.01% | 1333 |
|
|
2020
Q4 | $156K | Buy |
626
+42
| +7% | +$10K | ﹤0.01% | 1170 |
|
|
2020
Q3 | $132K | Buy |
584
+37
| +7% | +$7.68K | ﹤0.01% | 1108 |
|
|
2020
Q2 | $95K | Buy |
547
+23
| +4% | +$3.67K | ﹤0.01% | 1175 |
|
|
2020
Q1 | $66K | Buy |
524
+33
| +7% | +$4.95K | ﹤0.01% | 1164 |
|
|
2019
Q4 | $75K | Hold |
491
| – | – | ﹤0.01% | 1237 |
|
|
2019
Q3 | $64K | Hold |
491
| – | – | ﹤0.01% | 1255 |
|
|
2019
Q2 | $69K | Buy |
+491
| New | +$66.6K | ﹤0.01% | 1208 |
|
|
2018
Q4 | – | Sell |
-469
| Closed | -$63K | – | 1027 |
|
|
2018
Q3 | $63K | Buy |
469
+269
| +135% | +$33.2K | ﹤0.01% | 1107 |
|
|
2018
Q2 | $22K | Hold |
200
| – | – | ﹤0.01% | 1427 |
|
|
2018
Q1 | $21K | Buy |
200
+100
| +100% | +$10.8K | ﹤0.01% | 1308 |
|
|
2017
Q4 | $10K | Buy |
+100
| New | +$10.9K | ﹤0.01% | 1340 |
|
|
2017
Q3 | – | Sell |
-12
| Closed | -$1K | – | 1684 |
|
|
2017
Q2 | $1K | Hold |
12
| – | – | ﹤0.01% | 1504 |
|
|
2017
Q1 | $1K | Buy |
+12
| New | +$1.02K | ﹤0.01% | 1389 |
|
Other funds holding CRL
AI
Steward Partners Investment Advisory's CRL Position: Q2 2026 in Review
Steward Partners Investment Advisory reduced its Charles River Laboratories (CRL) stake by 6.5% in Q2 2026, selling an estimated $8.73K and leaving 702 shares worth $159K. The position accounts for ﹤0.01% of the portfolio, ranked #2345.
Steward Partners Investment Advisory first reported a position in CRL in Q1 2017 and has held it in 35 quarters since. The position peaked at $2.7M in Q4 2021. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Steward Partners Investment Advisory held 702 shares of Charles River Laboratories worth $159K as of Q2 2026.
- Steward Partners Investment Advisory sold 49 Charles River Laboratories shares in Q2 2026, an estimated $8.73K.
- Charles River Laboratories made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #2345 holding.
- Steward Partners Investment Advisory first reported a position in Charles River Laboratories in Q1 2017 and has held it in 35 quarters since.
- Steward Partners Investment Advisory's Charles River Laboratories position peaked at $2.7M in Q4 2021.
- 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.